Available Technologies

Find technologies available for licensing from UC Irvine.

No technologies match these criteria.
Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above

Magnetic Device for Preventing Upper Gastrointestinal Luminal Device Migration

A novel magnetic device designed to prevent migration of upper gastrointestinal intraluminal devices, increasing their clinical functionality and patient safety.

Fast-Curing Underwater Adhesive

A scalable and less toxic underwater adhesive developed from two small molecule precursors, providing fast and stable adhesion.

Microporous Layer/Catalyst Layer Integration For Electrolyzers

This invention combines the attributes of existing catalyst layer architectures to optimize reactions in solid polymer membrane electrolyzers.

Fast and Accurate Cardinality Estimation of Multi-Join Queries on Streams and Databases

Efficiently analyzing large volumes of information, as found in streaming data and big data applications, requires accurate cardinality estimates. This invention is capable of more accurately estimating cardinalities while using little memory and compute, as a result, speeding up query evaluation by as much as 50%.

Use of Ophthalmic Acid for treatment of Parkinson’s disease

Researchers at UC Irvine have identified Opthalmic acid (Ophthalmate, OA) for treatment of Parkinson’s disease (PD), a degenerative neurological disorder that affects 1-2% of people over the age of 60. PD is characterized by progressive motor symptoms such as tremor, rigidity, slowness of movement and difficulty with balance. There is currently no cure for Parkinson’s disease, only treatments to help manage the symptoms. Pharmacological strategies for treating PD depend mainly on replacing lost dopamine due to the degeneration of dopamine neurons in the substantia nigra compacta. Six decades after its initial use, L-3, 4-dihydroxyphenylalalnine (L-DOPA), the dopamine precursor, remains the standard of care for treatment of PD motor symptoms. L-DOPA can readily cross the blood-brain barrier (BBB) and is converted to dopamine by aromatic amino acid decarboxylase (AADC). Initial treatments with L-DOPA can provide great relief from motor symptoms, but over time its therapeutic effects diminish, and dyskinesia (abnormal involuntary movements) can increase in PD patients. Ophthalmic acid acts as a novel neurotransmitter to counteract the motor symptoms in animal models of PD, with a longer duration of action. Ophthalmic acid can be used as a novel drug for treatment of PD and other neurological disorders.

Biomaterial For Wound Healing

Researchers at UC Irvine have developed a novel biomaterial to heal and regenerate tissues for chronic wounds. The biomaterial, referred to as GelMA-AN, has immunomodulating properties engineered for complete incorporation into injured tissue while enhancing the regenerative healing activities of immune and stromal cells. It is based on a gelatin scaffold supplemented with Methacrylic Anhydride and immunomodulating apoptotic neutrophil cells. All components have high biocompatibility due to structural and biochemical similarities to the host wound environment. This combination of the hydrogel scaffold and apoptotic neutrophils has uncovered a wound healing mechanism that acts through immunomodulation to enhance regenerative healing. The mechanism works by modulating immune cells to drive them from inflammatory to healing activities that in turn stimulate stromal cells to repair the skin and regenerate health skin appendages such as vasculature.

Heterologous Synthesis of Nitrogenase in E. coli

A groundbreaking synthesis of simplified nitrogenase analogs in E. coli, facilitating nitrogen fixation in a non-diazotrophic organism.This synthesis provides the foundation for replacing fossil-fuel generated ammonia fertilizer with nitrogen fertilizer generated from a bacteria that is well-studied and already used in the biotech field.

Learned Image Compression With Reduced Decoding Complexity

The Mandt lab introduces a novel approach to neural image compression, significantly reducing decoding complexity while maintaining competitive rate-distortion performance.


5270 California Avenue / Irvine,CA
92697-7700 / Tel: 949.824.2683
  • Facebook
  • Twitter
  • Twitter
  • Twitter
  • Twitter